Open-Label Single-Arm Phase 2 Study of ALIMTA Plus Cisplatin in Korean Patients With Advanced Gastric Carcinoma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 4
- 主要终点
- Response rate according to RECIST criteria
研究概览
简要总结
Pemetrexed has shown an anti-tumor activity in advanced gastric cancer patients in a previous study, while cisplatin is widely used in the combination chemotherapy of gastric cancer. Pemetrexed has shown synergy with cisplatin in preclinical models and in various human cancers. The introduction of vitamin supplementation has made treatment with pemetrexed plus cisplatin safe and well tolerated. The present phase 2 study is an effort to determine the efficacy and safety of the combination of pemetrexed and cisplatin in Korean patients with gastric carcinoma who had no prior palliative chemotherapy for advanced disease. The patients, who will give their consent for participating in this study, will be screened for their eligibility and on meeting pre-defined study eligibility criteria, they will receive an intravenous therapy of the combination of pemetrexed and cisplatin for number of times that in the opinion of their treating physician is appropriate for them. A response rate of 30% is considered as the minimum activity level of interest for this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of adenocarcinoma of the stomach
- •Stage IV disease not amenable to curative surgery.
- •Disease status must be that of measurable disease as defined by RECIST criteria
- •Performance Status of 0 or 1 on the ECOG Scale and adequate organ function.
- •Signed informed consent from patient
排除标准
- •Prior palliative chemotherapy for advanced disease.
- •Known or suspected brain metastasis or Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
- •Concurrent administration of any other tumor therapy
- •Inability to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) 2 days before, the day of, and 2 days after the dose of ALIMTA plus cisplatin.
- •Inability or unwillingness to take folic acid, vitamin B12 supplementation, or dexamethasone.
结局指标
主要结局
Response rate according to RECIST criteria
次要结局
- The following time to event efficacy measures:
- o Duration of overall response for responding patients
- o Time to documented progressive disease
- o Time to treatment failure
- o Overall survival
- The quantitative and qualitative toxicity of pemetrexed plus cisplatin in this patient population